MedPath

AZIDUS BRASIL PESQUISA CIENTIFICA E DESENVOLVIMENTO LTDA

🇧🇷Brazil
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Phase 3
Terminated
Conditions
Chronic Kidney Disease
Anemia
Interventions
Drug: Epoetin alpha
First Posted Date
2012-09-28
Last Posted Date
2018-08-20
Lead Sponsor
Azidus Brasil
Target Recruit Count
92
Registration Number
NCT01695759
Locations
🇧🇷

Hospital de Ensino Padre Anchieta, São Bernardo do Campo, São Paulo, Brazil

🇧🇷

Fundação Universitária de Caxias do Sul - Instituto de Pesquisa Clínica para Estudos Multicêntricos, Caxias do Sul, Rio Grande Do Sul, Brazil

🇧🇷

Clínica Senhor do Bomfim Ltda, Feira de Santana, Bahia, Brazil

and more 7 locations

Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Heparin, Low-Molecular-Weight
First Posted Date
2012-09-25
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
36
Registration Number
NCT01692158
Locations
🇧🇷

LAL Clinica, Valinhos, Sao Paulo, Brazil

Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide

First Posted Date
2012-09-25
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
90
Registration Number
NCT01692717
Locations
🇧🇷

LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil

Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Heparin, Low-Molecular-Weight
First Posted Date
2012-09-25
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
32
Registration Number
NCT01692171
Locations
🇧🇷

LAL Clinica, Valinhos, Sao Paulo, Brazil

PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2012-09-14
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
28
Registration Number
NCT01685333
Locations
🇧🇷

LAL Clinica, Valinhos, Sao Paulo, Brazil

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2012-09-14
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
80
Registration Number
NCT01685359
Locations
🇧🇷

LAL Clinica, Valinhos, Sao Paulo, Brazil

Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.

Phase 3
Suspended
Conditions
Pregnancy; Fetomaternal Hemorrhage
Interventions
Biological: Immunoglobulin Anti-RhD
First Posted Date
2012-08-16
Last Posted Date
2022-11-02
Lead Sponsor
Azidus Brasil
Target Recruit Count
347
Registration Number
NCT01666249
Locations
🇧🇷

Instituto Tropical de Medicina Reprodutiva e Menopausa -INTRO, Cuiaba, Mato Grosso, Brazil

🇧🇷

Associação Educadora São Carlos AESC - Centro de Pesquisa HRPC, Canoas, Rio Grande Do Sul, Brazil

🇧🇷

Hospital São Lucas (Puc-Rs), Porto Alegre, Rio Grande Do Sul, Brazil

and more 2 locations

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.

Phase 1
Conditions
Healthy
Interventions
First Posted Date
2012-08-14
Last Posted Date
2012-08-14
Lead Sponsor
Azidus Brasil
Target Recruit Count
80
Registration Number
NCT01664221
Locations
🇧🇷

LAL Clinica, Valinhos, Sao Paulo, Brazil

PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects

Phase 1
Conditions
Healthy
Interventions
First Posted Date
2012-08-14
Last Posted Date
2012-08-14
Lead Sponsor
Azidus Brasil
Target Recruit Count
28
Registration Number
NCT01664195
Locations
🇧🇷

LAL Clínica, Valinhos, São Paulo, Brazil

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Phase 1
Conditions
Healthy
Interventions
First Posted Date
2012-07-30
Last Posted Date
2012-08-13
Lead Sponsor
Azidus Brasil
Target Recruit Count
44
Registration Number
NCT01652638
Locations
🇧🇷

LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, Brazil

© Copyright 2025. All Rights Reserved by MedPath